Literature DB >> 26919802

Cathepsin K inhibitors and antisclerostin antibodies. The next treatments for osteoporosis?

Roland Chapurlat1.   

Abstract

Entities:  

Keywords:  Antisclerostin; Cathepsin K; Odanacatib; Osteoporosis; Romosozumab

Mesh：

Substances：

Year:  2016        PMID： 26919802     DOI： 10.1016/j.jbspin.2015.09.008

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN： 1297-319X            Impact factor:   4.929


× No keyword cloud information.
  2 in total

1.  The selective cathepsin K inhibitor MIV-711 attenuates joint pathology in experimental animal models of osteoarthritis.

Authors:  Erik Lindström; Biljana Rizoska; Karin Tunblad; Charlotte Edenius; Alison M Bendele; Don Maul; Michael Larson; Neha Shah; Valerie Yoder Otto; Chris Jerome; Urszula Grabowska
Journal:  J Transl Med       Date:  2018-03-09       Impact factor: 5.531

2.  Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711.

Authors:  Erik Lindström; Biljana Rizoska; Ian Henderson; Ylva Terelius; Markus Jerling; Charlotte Edenius; Urszula Grabowska
Journal:  J Transl Med       Date:  2018-05-09       Impact factor: 5.531
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.